KR101255140B1 - 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도 - Google Patents

멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도 Download PDF

Info

Publication number
KR101255140B1
KR101255140B1 KR1020077011487A KR20077011487A KR101255140B1 KR 101255140 B1 KR101255140 B1 KR 101255140B1 KR 1020077011487 A KR1020077011487 A KR 1020077011487A KR 20077011487 A KR20077011487 A KR 20077011487A KR 101255140 B1 KR101255140 B1 KR 101255140B1
Authority
KR
South Korea
Prior art keywords
leu
ser
val
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077011487A
Other languages
English (en)
Korean (ko)
Other versions
KR20070085416A (ko
Inventor
마크 쿠닝함
베드라나 스토자노빅-수수릭
캐린 오네일
치치 황
제프리 루오
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20070085416A publication Critical patent/KR20070085416A/ko
Application granted granted Critical
Publication of KR101255140B1 publication Critical patent/KR101255140B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077011487A 2004-10-25 2005-10-25 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도 Expired - Fee Related KR101255140B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62196004P 2004-10-25 2004-10-25
US60/621,960 2004-10-25
PCT/US2005/038431 WO2006047535A2 (en) 2004-10-25 2005-10-25 Melanocortin receptor binding mimetibodies, compositions, methods and uses

Publications (2)

Publication Number Publication Date
KR20070085416A KR20070085416A (ko) 2007-08-27
KR101255140B1 true KR101255140B1 (ko) 2013-04-22

Family

ID=36228385

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011487A Expired - Fee Related KR101255140B1 (ko) 2004-10-25 2005-10-25 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도

Country Status (28)

Country Link
US (1) US20060105951A1 (enExample)
EP (1) EP1812046B1 (enExample)
JP (1) JP2008517605A (enExample)
KR (1) KR101255140B1 (enExample)
CN (1) CN101437540B (enExample)
AT (1) ATE501731T1 (enExample)
AU (1) AU2005299440B2 (enExample)
BR (1) BRPI0518411A2 (enExample)
CA (1) CA2585287A1 (enExample)
CY (1) CY1111486T1 (enExample)
DE (1) DE602005026970D1 (enExample)
DK (1) DK1812046T3 (enExample)
EA (1) EA200700944A1 (enExample)
EC (1) ECSP077416A (enExample)
ES (1) ES2363023T3 (enExample)
HR (1) HRP20110405T1 (enExample)
IL (1) IL182683A0 (enExample)
MA (1) MA28943B1 (enExample)
ME (1) ME01234B (enExample)
MX (1) MX2007004974A (enExample)
NO (1) NO20072499L (enExample)
PL (1) PL1812046T3 (enExample)
PT (1) PT1812046E (enExample)
RS (1) RS51789B (enExample)
SI (1) SI1812046T1 (enExample)
TN (1) TNSN07157A1 (enExample)
WO (1) WO2006047535A2 (enExample)
ZA (1) ZA200704260B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
US7790671B2 (en) * 2005-10-07 2010-09-07 Codman & Shurtleff, Inc. Implantable pump for protein delivery for obesity control by drug infusion into the brain
CA2727317C (en) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US20090305960A1 (en) * 2008-06-09 2009-12-10 Palatin Technologies, Inc Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
US8614185B2 (en) * 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
CA2781402C (en) 2009-11-23 2017-03-21 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
CN113272330B (zh) * 2019-03-02 2024-07-26 南通壹宸生物医药科技有限公司 一种双特异抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2002006316A2 (en) * 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
WO2004002424A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545608A4 (en) * 2002-06-28 2006-09-13 Centocor Inc CH1-DELETED MAMMED MUICETIC BODIES, COMPOSITIONS, METHODS AND APPLICATIONS
CA2563379A1 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033658A1 (en) 1998-12-09 2000-06-15 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
WO2002006316A2 (en) * 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
WO2004002424A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
MX2007004974A (es) 2007-10-17
NO20072499L (no) 2007-07-16
WO2006047535A2 (en) 2006-05-04
HK1106445A1 (en) 2008-03-14
US20060105951A1 (en) 2006-05-18
CN101437540B (zh) 2012-12-19
CA2585287A1 (en) 2006-05-04
ES2363023T3 (es) 2011-07-19
EP1812046A2 (en) 2007-08-01
JP2008517605A (ja) 2008-05-29
SI1812046T1 (sl) 2011-06-30
RS51789B (sr) 2011-12-31
ZA200704260B (en) 2009-03-25
EA200700944A1 (ru) 2008-04-28
AU2005299440B2 (en) 2011-12-15
ME01234B (me) 2013-06-20
EP1812046A4 (en) 2009-11-11
DE602005026970D1 (de) 2011-04-28
AU2005299440A1 (en) 2006-05-04
PL1812046T3 (pl) 2011-08-31
PT1812046E (pt) 2011-06-28
HRP20110405T1 (hr) 2011-06-30
MA28943B1 (fr) 2007-10-01
CY1111486T1 (el) 2015-08-05
BRPI0518411A2 (pt) 2008-11-18
WO2006047535A3 (en) 2008-09-04
ATE501731T1 (de) 2011-04-15
TNSN07157A1 (en) 2008-11-21
IL182683A0 (en) 2007-09-20
ECSP077416A (es) 2007-05-30
CN101437540A (zh) 2009-05-20
DK1812046T3 (da) 2011-06-06
EP1812046B1 (en) 2011-03-16
KR20070085416A (ko) 2007-08-27

Similar Documents

Publication Publication Date Title
JP7657249B2 (ja) 治療用ヌクレアーゼ組成物および方法
KR101255140B1 (ko) 멜라노코르틴 수용체 결합 모방체, 조성물, 방법 및 용도
US20030220274A1 (en) GLP-1 gene delivery for the treatment of type 2 diabetes
EP2214690B1 (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
CN107056951A (zh) Cd86拮抗物多靶点结合蛋白
CN113493519B (zh) 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2008133873A9 (en) Fgf-binding fusion proteins
DK2538968T3 (en) PROCEDURE FOR THE PREPARATION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALFA MANNOSIDASE
ES2865443T3 (es) Transformante de levadura recombinante y proceso de preparación del fragmento Fc de inmunoglobulina mediante el empleo del mismo
KR102510154B1 (ko) 비만유래 2형 당뇨 예방 및 치료를 위한 내장지방 대식세포 표적 비바이러스성 유전자／전달체 복합체
CN110423776B (zh) 表达重组凝血因子fix的载体及其构建方法和应用
HK1106445B (en) Melanocortin receptor binding mimetibodies, compositions, methods and uses
KR20130059526A (ko) 인간 뼈 형성촉진효과를 위해 인간 ｂｍｐ2/7-ｐｔｄ 발현벡터를 통해 형질전환된 세포주 및 이 형질전환된 세포주를 이용한 3차원 세포 배양방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20160318

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170317

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180411

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180411